

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 85202085.8

(22) Date of filing: 16.12.85

(51) Int. Cl.⁴: **A 61 K 31/495**

C 07 D 327/06, C 07 D 277/62
 C 07 D 265/36, C 07 D 261/20
 C 07 D 231/56, C 07 D 215/38
 C 07 D 333/54, C 07 D 315/00
 C 07 D 271/12, C 07 D 263/54

(30) Priority: 21.12.84 NL 8403917

(43) Date of publication of application:
06.08.86 Bulletin 86/32

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: DUPHAR INTERNATIONAL RESEARCH B.V.
C.J. van Houtenlaan 36
NL-1381 CP Weesp(NL)

(72) Inventor: Hartog, Jan
OCTROOIBUREAU ZOAN BV Apollolaan 151
NL-1077 AR Amsterdam(NL)

(72) Inventor: Olivier, Berend
OCTROOIBUREAU ZOAN BV Apollolaan 151
NL-1077 AR Amsterdam(NL)

(72) Inventor: van Wijngaarden, Ineke
OCTROOIBUREAU ZOAN BV Apollolaan 151
NL-1077 AR Amsterdam(NL)

(72) Inventor: Kruse, Cornelis Gerrit
OCTROOIBUREAU ZOAN BV Apollolaan 151
NL-1077 AR Amsterdam(NL)


(72) Inventor: van der Heyden, Johannes Antonius Maria
OCTROOIBUREAU ZOAN BV Apollolaan 151
NL-1077 AR Amsterdam(NL)

(72) Inventor: van Dalen-van der Aa, Dirkje Antonia
OCTROOIBUREAU ZOAN BV Apollolaan 151
NL-1077 AR Amsterdam(NL)

(74) Representative: Muls, Maarten et al.
OCTROOIBUREAU ZOAN B.V. P.O. Box 140
NL-1380 AC Weesp(NL)

(54) New pharmaceutical compositions having a psychotropic activity.


(57) The invention relates to new compositions with psychotropic activity which comprise a compound of formula 1 as the active substance. The compounds of formula 1 are for the greater part new compounds. The invention therefore also relates to these new compounds and to the preparation thereof in a manner known for the synthesis of analogous compounds.



New pharmaceutical compositions having a psychotropic activity.

The invention relates to new pharmaceutical compositions having a psychotropic activity, to new piperazine derivatives which may be used in such compositions as the active substance, and to the preparation of the said compositions and active compounds.

It was found that compounds of the general formula 1



wherein

$-R_1$ is alkyl, cycloalkyl, optionally esterified hydroxyalkyl, alkoxyalkyl, optionally substituted phenyl or heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkyl-, alkoxy-, amino-, mono- or dialkylaminocarbonyl, nitro, amino, mono- or dialkylamino, arylamino, cyano, halogen, trifluoromethyl, trifluoromethoxy, optionally esterified hydroxyl, alkyl- or aminosulphonyl or -sulphinyl, mono- or dialkylaminosulphonyl or -sulphinyl, and p has the value 0-3;

$-R_2$ is an alkyl group and n and q can have the value 0 or 1;

$-R_3$ may have the same meaning as R_1 , or is alkylidene, an oxo or thioxogroup, and m has the value 0-2;

$-A$ forms, with the two carbon atoms of the phenyl group, an optionally entirely or partly unsaturated cyclic group having 5-7 atoms in the ring, which comprises 1-3 hetero atoms from the group O, S and N, with the proviso that the sum of the number of oxygen and sulphur atoms is at most 2,


and the acid addition salts of these compounds have interesting psychotropic properties.

As a halogen atom, R_1 is preferably fluoro, chloro or bromo, and as an alkyl group, for example, a straight
5 or branched, saturated or unsaturated group having 1-5 carbon atoms.

When R_2 is an alkyl group, this is preferably the methyl group or ethyl group.

As a hydroxyalkyl group, the group R_3 preferably
10 comprises 1-3 carbon atoms.

When R_1 or R_3 is an esterified hydroxyl group or hydroxylalkyl group, the ester group preferably has the formula



in which R_4 is alkyl, aralkyl, aryl, heteroaryl, hetero
aralkyl, and alkyl may be branched or unbranched, and the
(hetero) aryl part may optionally be substituted, or R_4
20 may be an alkoxy, heteroalkoxy or dialkylamino group, in which the two alkyl groups can form a heterocyclic ring with the nitrogen atom.

When R_1 or R_3 is an etherified hydroxyl group or hydroxyalkyl group, the ether group preferably has the
25 formula $-O-R_5$, wherein R_5 is a straight, branched or cyclic alkyl group having 1-5 C-atoms, or an alkoxyalkyl group having 1 or 2 C-atoms in both the alkoxy part and in the alkyl part thereof.

Compounds which are preferred on the basis of their
30 activity pattern are:

- a) 1-[5-(1,4-benzodioxanyl)] piperazine,
- b) 1-[8-(1,3-benzodioxanyl)] piperazine,
- c) 1-[7-(benzofuranyl)] piperazine,
- d) 1-[4-(1,3-benzodioxolyl)] piperazine,
- 35 e) 1-[5-(2-methoxymethyl-1,4-benzodioxanyl)] piperazine,
- f) 1-[7-(5-fluorobenzofuranyl)] piperazine,

- g) 1-[8-(1,2,3,4-tetrahydroquinolyl)]piperazine,
h) 1-[8-(2-oxo-1-benzopyranyl)]piperazine,
i) 1-[8-(2H-1-benzopyranyl)]piperazine,
j) 1-[5-(2-methyl-1,4-benzodioxanyl)]piperazine,
5 k) 1-[7-(4-fluorobenzofuranyl)]piperazine,
l) 1-[8-(isoquinolyl)]piperazine,
m) 1-[7-(4-bromobenzofuranyl)]piperazine,
n) (+)-1-[5-(2-methoxymethyl-1,4-benzodioxanyl)]piperazine,
o) 1-[7-(4-methylbenzofuranyl)]piperazine,
10 p) 1-[7-(4-chlorobenzofuranyl)]piperazine,
q) 1-[7-(5-chlorobenzofuranyl)]piperazine.

The so-called prodrugs of the compounds of formula 1, i.e. derivatives of compounds of the formula 1 which are inactive as such and which after administration are converted in the body into active compounds of formula 1 also belong to the invention.

When a chiral carbon atom is present, both the racemate and the individual isomers belong to the invention.

Suitable acids with which the compounds of formula 1 can form pharmaceutically acceptable acid additon salts are, for example, hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, and organic acids such as citric acid, fumaric acid, maleic acid, tartaric acid, acetic acid, benzoic acid, p-toluenesulphonic acid, methanesulphonic acid, and naphthalenesulphonic acid.

The above-described compounds of formula 1 have a psychotropic activity and are hence excellently suitable for the treatment of affections or diseases which are the result of disturbances in the central nervous system, for example, psychoses, aggression, fear, depression, etc. Some of the compounds moreover have also a good central analgetic activity.

Dependent on the meanings of the symbols A, R_1 - R_3 , \underline{m} , \underline{n} , \underline{p} and \underline{q} some compounds of the formula 1 have a strong thrombolytic activity. This property makes these compounds particularly suitable for use in the treatment of hematological disorders.

An important advantage of the present compounds of formula 1 is that their activity is very specific. It was found, for example, that in mice the antiaggressive activity is not associated with undesired sedative effects.

5 As a rule the antipsychotic activity is produced without the side effects, which are generally considered to be undesired, as a result of dopaminolytic and sedative activity.

10 Dependent on the meanings of the groups A and R_1-R_3 , both the antiaggressive activity and the antipsychotic activity may be most prominent.

15 The antiaggressive activity of the compounds was measured in a test suitable for that purpose on isolated mice (Advances in Pharmacol. 5, (1967), 79). In this test, male albino mice were kept isolated for a period of 4 weeks and were then selected for the test on the basis of fighting behaviour present. The selection criterion is the occurrence of 3 or more fighting periods within 3 minutes after a mouse which had not been kept isolated is placed in the cage of the mouse which had been kept isolated.

20 The compounds to be investigated were administered orally to the selected mice. Five mice per dose were used. Sixty minutes after administration of the compound to be investigated, the animals were again evaluated for fighting behaviour. The compound to be investigated is inactive in the administered dose when in this case also 3 or more fighting periods were observed within 3 minutes after a mouse which had not been kept isolated was placed in the cage of the mouse which had been kept isolated. The

25 ED_{50} -value in mg of active substance per kg of body weight was calculated from the results obtained.

30 The compounds according to the invention have an ED_{50} -value which is smaller than 20 mg/kg and for most of the compounds the ED_{50} -value is 0.1-5 mg/kg.

Due to the strong antiaggressive activity and the absence of undesired side effects, for example, sympatholytic, dopaminolytic, muscle relaxing and sedative properties, the compounds are excellently suitable for use in the treatment of intra- and extrapunitive behaviour and overt aggressive behaviour in man and animal.

For use in humane medicine are to be considered first of all the control of aggressive symptoms in psychiatric diseases and serious forms of psychopathological aggression.

As application possibilities in the veterinary field are to be considered especially those forms of aggression which occur in the transport of agricultural domestic animals and the mixing of groups of these animals.

The antipsychotic activity of the compounds of formula 1 was determined in a test procedure in which the suppression of conditioned behaviour in test animals was measured according to procedures known per se. The compounds are considered to be active if they show at least a suppression of 50% of the conditioned behaviour after oral administration in dosages of 50 mg/kg or less. The dopaminolytic activity of these compounds can be determined according to known behavioural or biochemical tests, for example, induction of catalepsy, increasing of the dopamine synthesis or conversion rate in the central nervous system, and by the affinity to dopamine receptors which is determined by displacement of a radioactive labelled ligand in a tissue homogenate.

The sedative activity of these compounds was studied in a test in which the influencing of the spontaneous locomotoric activity of test animals is measured according to known methods.

For the active compounds of formula 1 it was found that generally dopaminolytic and sedative effects do not occur in dosages which are at least a factor three higher

than the dosages which give 50% suppression of the conditioned behaviour.

The quantity, frequency and way of administration may differ for each individual case, also dependent on the nature and the severity of the disturbances. A dosage of 5-500 mg and preferably of 25-150 mg daily are generally suitable for humane application.

For veterinary purposes the dosage preferably is 0.1-10 mg/kg of body weight.


The analgetic activity of the compounds was determined in an analgetic test in mice (Brit. J. Pharm. 9, (1954), 280). In this test the pain stimulus was generated by placing bulldog clips on the tailhead of a mouse. The animals try to remove the pain stimulus by biting. The non-occurrence of the pain response after administration of test substances is a measure of the analgetic activity. The compounds to be tested were administered orally. Five mice were used per dose. Sixty minutes after the administration of the compounds to be tested, the occurrence of the pain response was established. From the results obtained the ED₅₀-values in mg/kg of active substance per kg of body weight were calculated.

The thrombolytic activity is determined using the method described by Kumada et al (Thrombosis Research, 18, (1980), 189-203).

The active compounds according to the invention and their salts can be processed, according to known standard methods, to compositions such as pills, tablets, coated tablets, capsules, powders, injection liquids, and the like while using the conventional auxiliary substances, for example, solid and liquid carrier materials.

The compounds of formula 1 are new compounds with the exception of the compounds wherein n and q are 0, and A together with the two carbon atoms of the phenyl group forms a heterocyclic group having 5 or 6 ringatoms, which as the only hetero atom contains one nitrogen atom at the m ta position in relation to the piperazine group (some of these compounds are known from French patent specification


81.23744), and compounds in which n and q are 0, and the group of formula 2




10 is a 4-(or 7-)benzimidazolyl group which may be substituted in position 2 with alkyl or phenyl, or a 7-indolyl group, or a 4-(or 7-)benzotriazolyl group (which compounds are known from Netherlands Patent Application 82.01708), or a 5-(or 8-)carbo (or 3,4-dihydrocarbo-)styryl group
 15 (which compounds are known from Netherlands patent application 81.04923), or an 8-quinolinyl group (which compound is known from Ber. 74B, (1941), pp. 1661-1663).

The new compounds according to the invention can be prepared in a manner known for the synthesis of analogous
 20 compounds (see, for example, United States Patent Specification 2,976,290 and J. Med. Chem. 8, (1965), pp. 104-107).

The compounds can be obtained, for example, by reaction of a compound of formula 3



30 with a compound of formula 4,




in which formula L is a so-called leaving group, preferably chlorine, bromine, alkyl-SO₃ or aryl-SO₃.

This reaction may be carried out both in an inert apolar organic solvent, and in a protic polar solvent. Examples of suitable solvents are chlorobenzene, toluene, pyridine, acetonitrile, lower aliphatic alcohols, for example, ethanol, propanol and butanol. In order to bind the releasing acid, an acid binder, for example NaHCO₃ or K₂CO₃ or an organic base, for example, triethylamine, may be used.


The reaction temperature usually is between room temperature and the boiling-point of the solvent used.

It is sometimes necessary or desired in this mode of preparation first to replace the hydrogen atom at the nitrogen atom in the starting material of formula 4 by a protective group, for example, the benzyl group, an aryloxycarbonyl group or alkoxycarbonyl group the alkoxy group of which comprises 1-4 C-atoms. Said protective group can then be removed from the resulting final product by means of the methods conventionally used for this purpose, for example, by catalytic hydrogenation or by acid hydrolysis. Conventional solvents are lower aliphatic alcohols and aliphatic esters thereof or aqueous mineral acid. The reactions are carried out at temperatures between room temperature and reflux temperature of the solvent used.

The compounds of formula 1 can furthermore be obtained by reduction of a compound of formula 5



or formula 6,




5

in which the symbols have the above-mentioned meanings. This reduction reaction may be carried out, for example, with suitable reduction agents, for example LiAlH_4 or a $\text{BH}_3 \cdot \text{S}(\text{CH}_3)_2$ -complex in a suitable solvent, for example, ether or tetrahydrofuran. The reaction is carried out at temperatures between room temperature and the reflux temperature of the solvent used. This method can be used readily only when besides the keto group or keto groups to be reduced, no other groups sensitive to reduction are present in the starting substances of formula 5 or 6.

15


Another suitable method of preparing the compounds of formula 1 is the reaction of a compound of formula 7

20



25

with a piperazine of formula 8,




30

in which A, R_1 - R_3 , p , n , q and m have the above-mentioned meanings and L is a leaving group, for example, a halogen atom or nitro group. This reaction is carried out

35

in a suitable organic solvent, for example, toluene, xylene, or a mono- or polyalcohol of higher boiling-point, at the reflux temperature of the solvent used.

The compounds of formula 1 can further be prepared by reaction of a compound of formula 9




with NaNO_2 in the manner described, inter alia, in J.Chem.Soc. 1971, 3994-3999 in a sulphuric acid or hydrochloric acid medium, in which the resulting diazonium salt is decomposed with, for example, 50% hypophosphoric acid. The reaction is carried out at temperatures between 0°C and room temperature.

Some compounds of formula 1 can furthermore be obtained by conversion of another compound of formula 1. For example, compounds of formula 1, in which R_1 and/or R_3 is/are an esterified hydroxyl function, can be converted by hydrolysis via a method known per se into compounds in which R_1 and/or R_3 is/are hydroxyl. The reverse is also possible.

Another possibility is to saturate or introduce a double bond in compounds of formula 1, by hydrogenation or dehydrogenation, dependent on the structure.

Moreover, compounds of the formula 1, wherein \underline{n} and/or \underline{q} has the value 1 can be obtained by introducing one or two groups R_2 starting with the corresponding compounds of the formula 1 wherein \underline{n} and/or \underline{q} has the value 0. According to this process (Chem. Rev. 78, (1978), 275 and 84, (1984), 471) a compound of the formula 1 is converted into a compound of the formula 10

11




5

wherein R_1 - R_3 , m , n , p and q have the above meanings, and R_6 is an activating group, for example a nitroso group. Then the compound of formula 10 is alkylated with a compound R_2 -L, wherein R_2 and L have the above meanings. After the alkylation the activating group R_6 is removed in a way known per se, whereby the desired compound of formula 1 is obtained.

The reaction is carried out in a suitable organic solvent such as for example a lower alkane, diethyl ether or tetrahydrofuran, in the presence of a strong base, for example aryl- or alkyl lithium or a lithium dialkylamine, at temperatures preferably between -100°C and 0°C .

Finally, compounds of formula 1 can be obtained, dependent on the meaning of A, by converting compounds of formula 11



25

into compounds of formula 1 by a cyclisation reaction. This cyclisation generally takes place, dependent on the meanings of Z and Z' and the desired meaning of A, via methods known per se for this type of substances or analogous thereto.

The starting materials to be used in the above-described methods can be obtained, in so far as these are new compounds, in a manner known for the synthesis of analogous compounds.

35

The invention will be further described with reference to the ensuing specific examples.

EXAMPLE I

5 1-[5-(1,4-benzodioxanyl)] piperazine, hydrochloride.

128 Mmol (23.9 g) of 5-amino-1,4-benzodioxan and 140 mmol (25.0 g) of bis-(2-chloroethyl)amine HCL were suspended in 250 ml of chlorobenzene. The mixture was heated at 130° C for 66 hours while stirring.

10 The reaction mixture was cooled to 90° C and diluted with 200 ml of ethyl acetate. The solid was filtered off and washed with ethyl acetate. The crude substance was recrystallized from ethanol and the title compound was obtained having a melting-point of 256-258° C.

15

EXAMPLE II

1-[8-(1,3-benzodioxanyl)] piperazine, hydrochloride.

18.7 Mmol (5.8 g) of 1-[8-(1,3-benzodioxanyl)]-4-benzylpiperazine were dissolved in 150 ml of 96% ethanol after which 1 g of 10% palladium on carbon was added. The mixture was then hydrated at 50° C with 450 ml of hydrogen. The reaction mixture was filtered over hyflo and the filtrate was evaporated to dryness under reduced pressure.

20 The evaporation residue was dissolved in 100% ethanol and 1 equivalent of hydrochloric acid in ethanol was added hereto. The solution was treated with carbon and after filtration over hyflo the filtrate was diluted with ether. The title compound was isolated with a melting-point of
25 217-219° C.
30

EXAMPLE 111

1-[5-(1,4-benzodioxanyl)] -3-methylpiperazine, hydrochloride.

- 5 64 Mmol (16,7 g) of 1-[5-(1,4-benzodioxanyl)] -3-methylpiperazine-2,6-dione were dissolved under an atmosphere of nitrogen in 200 ml of tetrahydrofuran distilled over lithium aluminium hydride.
- 10 170 Mmol (12.9 g) of borane-dimethyl sulphide complex (16.3 ml) were carefully added to this solution, after which the whole was heated slowly to 40° C. During the moderately exotherm reaction, a mixture of dimethylsulphide and tetrahydrofuran was distilled off, the total volume of the reaction mixture being kept constant by simultaneously adding dropwise tetrahydrofuran. After 300 ml of
- 15 distillate had been collected, the reaction mixture, in which a precipitate had formed, was cooled to -10° C. At this temperature, 80 ml of 6 N hydrochloric acid were added dropwise, after which the reaction mixture, without
- 20 a cooling bath, slowly reached room temperature. After leaving to stand for 16 hours, the mixture was heated to reflux in which a bright solution was formed and tetrahydrofuran was distilled off. While cooling with ice, 270 ml of 2 N sodium hydroxide were added to this solution,
- 25 after which the mixture was extracted with 3 x 300 ml of ethyl acetate. The organic layer was washed with water and then dried on sodium sulphate and evaporated to dryness in vacuo. The residue after evaporation was dissolved in a mixture of ethyl acetate-ethanol and 1 equivalent of hydrochloric acid in ethanol was added hereto, after which
- 30 the title compound was obtained with a melting-point of 220-224° C.

EXAMPLE IV5-(1-piperazinyl)quinoxalin, hydrochloride.

0.2 Mol (33.5 g) of 5-chloroquinoxalin and 2.1 mol (184 g) of piperazine were mixed in 180 ml of ethylene glycol and refluxed for 20 hours.

5 The reaction mixture was poured on ice and acidified with concentrated hydrochloric acid and then extracted with 3 x 200 ml of ether. The water layer was made alkaline while cooling with ice, with 50% sodium hydroxide and then extracted with 3 x 600 ml of methylene chloride. The combined methylene chloride solution was washed successively
10 with 1 l of 1N sodium hydroxide and a mixture of 925 ml of a saturated saline solution and 75 ml of 50% potassium hydroxide. The organic solution was dried on sodium sulphate and was then evaporated to dryness in vacuo. The
15 residue was chromatographed over silica gel with a mixture of methylene chloride, methanol, and 25% ammonia (92 : 7.5 : 0.5) as eluent. The resulting free base was dissolved in ethanol and 1 equivalent of hydrochloric acid in ethanol was added. The title compound was obtained with a melting-point of 271-272° C.
20

EXAMPLE V1-[5-(2-hydroxymethyl-1,4-benzodioxanyl)] piperazine, dihydrochloride.

25 6,6 Mmol of 1-[5-(2-benzoyloxymethyl-1,4-benzodioxanyl)]piperazine were suspended in 100 ml of ethanol, after which a solution of 0.95 g of 85% KOH in 10 ml of water was added in one portion. After stirring at room temperature for 2.5 hours, the suspension was concentrated by evaporation at reduced pressure. The residue was
30 then extracted with chloroform. The residue obtained after evaporation was finally converted with 2 equivalents of hydrochloric acid into the dihydrochloride of the title compound with a melting-point of 228-233° C.

EXAMPLE VI

1-[8-(1,2,3,4-tetrahydroquinolinyl)] piperazine, dihydrochloride.

7.5 g Of $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$ were added while stirring at
 5 10-15° C to 10.5 mmol of 1-(8-quinolinyl) piperazine in 75
 ml of methanol. 11.9 g Of NaBH_4 were then added in por-
 tions in approximately 30 hours at 10-20° C. The reaction
 mixture was worked up by pouring in a mixture of 70 ml of
 water and 30 ml of concentrated hydrochloric acid. After
 10 heating at 90° C for 20 minutes, the mixture was cooled
 and 20 ml of 50% NaOH solution was added. The title com-
 pound was finally obtained by extraction with chloroform
 and a chromatographic purification over silica gel, suc-
 ceeded by the preparation of the dihydrochloride with 2
 15 equivalents of hydrochloric acid in ethanol. Melting-point
 330-334° C.


EXAMPLE VII

1-[4-(3-methyl-1,2-benzisoxazolyl)] piperazine fumarate.

20 86.9 Mmol of 1-(3-fluoro-2-acetyloxim-phenyl) piper-
 zine were dissolved in 100 ml of DMSO, after which 6.7 g
 of 85% KOH were added. The mixture was poured in 500 ml of
 water, while stirring, and extracted with 3 x 300 ml of
 ethyl acetate. The product obtained after drying on mag-
 25 nesium sulphate and evaporation was dissolved in hot etha-
 nol, after which 1 equivalent of fumaric acid was added in
 150 ml of hot ethanol.

The title compound was sucked off after crystallization
 and had a melting-point of 216-219° C.

30 Analogously to the methods described in the Examples I
 to VII, the compounds of formula 12



40 recorded in the table below were prepared according to the
 method of the specific example also mentioned in the table:

TABLE
















Comp.No.	X	$(R_2)_n$	$(R_2)_q$	Salt	Melt.-point (°C)	Method of Ex.
1		H	H	HCl	222-224	I
2		H	H	HCl	256-258	I
3		H	H	HCl	266-269	I
4		Me	H	HCl	220-224	III
5		H	H	2HCl	228-233	V
6		H	H	2HCl	226-230	V
7		H	H	2HCl	236-240	V
8		H	H	HCl	186-189	I
9		H	H	HCl	179-181	I
10		H	H	HCl	228-235	V
11		H	H	FUM.	125 (decomp.)	V
12		H	H	HCl	217-219	II
13		H	H	HCl	266 (decomp.)	II
14		H	H	HCl	261-265	I
15		H	H	HCl	190-192	I

TABLE (cont.)

Comp.No.	X	$(R_2)_n$	$(R_2)_q$	Salt	Melt.-point (°C)	Method of Ex.
16		H	H	2HCl	215-218	I
17		H	H	HCl	235-240	I
18		H	H	HCl	288-290	I
19		H	H	2HCl	196-199	I
20		H	H	HCl	240-245	I
21		H	H	HCl	240	II
22		H	H	0.5 FUM.	226-228	I
23		H	H	FUM.	195-196	I
24		H	H	FUM.	216-219	VII
25		H	H	-	oil	I
26		H	H	HCl	271-272	IV
27		H	H	2HCl	216-222	I
28		H	H	2HCl	330-334	VI
29		H	H	2.1HCl	215-221	I

TABLE (cont.)

Comp.No.	X	(R ₂) _n	(R ₂) _q	Salt	Melt.-point (°C)	Method of Ex.
30		Me(cis)	Me	HCl	277-283	III
31		H	H	HCl	250 (dec.)	I
32		H	H	maleaat resin		II
33		H	H	2.HCl	195-197,5	II
34		H	H	2.HCl	295-300	VI
35		H	H	HCl	250 (dec.)	IV
36		H	H	2.HCl	219-220	II
37		H	H	FUM.	208-211	VI
38		H	H	2.HCl	190-193,5	II
39		H	H	FUM.	164-166	II
40		H	H	2.HCl	216-218	II
41		H	H	2.HCl	240-245	VI
42		H	H	2.HCl	280-290	V
43		H	H	2.HCl	257,5-265	VI
44		H	H	2.HCl	276-280	I

TABLE (cont.)






























Comp.No.	X	$(R_2)_n$	$(R_2)_q$	Salt	Melt.-point (°C)	Method of Ex.
45		H	H	2.HCl	207-212	I
46		H	H	2.HCl	224 (dec.)	I
47		H	H	2.HCl	280-285	II
48		H	H	2.HCl	195-197	II
49		H	H	2.HCl	196-200	II
50		H	H	2.HCl	263-265	II
51		H	H	HCl	228-229	I
52		H	H	2.HCl	284-288	VI
53		H	H	2.HCl	300 (dec.)	I
54		H	H	2.HCl	240 (dec.)	IV
55		H	H	HCl	208-210	I
56		H	H	HCl	236-240	I
57		H	H	HCl	235, 5-236	VI
58		H	H	HCl	228-234	I
59		H	H		resin	II

TABLE (cont.)

Comp.No.	X	(R ₂) _n	(R ₂) _q	Salt	Melt.-point (°C)	Method of Ex:
60		H	H	2.HCl	186-190	I
61		H	H	free base	195-198	VI
62		H	H	HCl	310-330	II
63		H	H	HCl	200-205	I
64		H	H	2.HCl	233 (dec.)	II
65		H	H	HCl	290 (dec.)	I
66		H	H	2.HCl	200-202	II
67		H	H	HCl	285-286	II
68		H	H	HCl	330-331	VI
69		Me(trans)	Me	HCl	236-240	III
70		H	H	HCl	170-173	I
71		H	H	HCl	196-198	I
72		H	H	HCl	256-258	J

CLAIMS

1. Pharmaceutical composition which comprises a piperazine derivative as the active substance, characterized in that as a psychotropically active substance it comprises at least one compound of formula 1,



in which

- 15 -R₁ is alkyl, cycloalkyl, optionally esterified hydroxy-alkyl, alkoxyalkyl, optionally substituted phenyl or heteroaryl, alkoxy, aryloxy, alkylthio, arylthio, alkyl-, alkoxy-, amino-, mono- or dialkylaminocarbonyl, nitro, amino, mono- or dialkylamino, arylamino, cyano, halogen, trifluoromethyl, trifluoromethoxy, optionally esterified hydroxyl, alkyl- or aminosulphonyl or -sulphinyl, mono- or dialkylaminosulphonyl or -sulphinyl and p has the value 0-3;
- 20 -R₂ is an alkyl group and n and q can have the value 0 or 1;
- 25 -R₃ may have the same meanings as R₁, or is alkylidene, an oxo or thioxogroup, and m has the value 0-2;
- A forms, with the two carbon atoms of the phenyl group, an optionally fully or partly unsaturated cyclic group having 5-7 atoms in the ring, which
- 30 comprises 1-3 hetero atoms from the group O, S and N, with the proviso that the sum of the number of oxygen and sulphur atoms is at most 2, or contains an acid addition salt, prodrug or enantiomer thereof.
- 35 2. A composition as claimed in Claim 1, characterized in that the active substance has an antiaggressive effect.
3. A composition as claimed in Claim 1, characterized in that the active substance has an antipsychotic effect.

4. A composition as claimed in Claim 1, characterized in that the active substance is

- a) 1-[5-(1,4-benzodioxanyl)] piperazine,
- b) 1-[8-(1,3-benzodioxanyl)] piperazine,
- 5 c) 1-[7-(benzofuranyl)] piperazine,
- d) 1-[4-(1,3-benzodioxolyl)] piperazine,
- e) 1-[5-(2-methoxymethyl-1,4-benzodioxanyl)] piperazine,
- f) 1-[7-(5-fluorobenzofuranyl)] piperazine,
- g) 1-[8-(1,2,3,4-tetrahydroquinolyl)]piperazine,
- 10 h) 1-[8-(2-oxo-1-benzopyranyl)]piperazine,
- i) 1-[8-(2H-1-benzopyranyl)]piperazine,
- j) 1-[5-(2-methyl-1,4-benzodioxanyl)]piperazine,
- k) 1-[7-(4-fluorobenzofuranyl)]piperazine,
- l) 1-[8-(isoquinolyl)]piperazine,
- 15 m) 1-[7-(4-bromobenzofuranyl)]piperazine,
- n) (+)-1-[5-(2-methoxymethyl-1,4-benzodioxanyl)]piperazine,
- o) 1-[7-(4-methylbenzofuranyl)]piperazine,
- p) 1-[7-(4-chlorobenzofuranyl)]piperazine,
- q) 1-[7-(5-chlorobenzofuranyl)]piperazine.
- 20 a salt or prodrug thereof.

5. A method of preparing pharmaceutical compositions by bringing a pharmacologically active piperazine derivative into a form suitable for administration, characterized in that compositions with psychotropic activity are
25 prepared by using a compound of formula 1, in which R_1 - R_3 , A, p, n, q and m have the meanings given in Claim 1, or an acid addition salt, prodrug or enantiomer thereof as the active substance.

6. A method as claimed in Claim 5, characterized in
30 that


- a) 1-[5-(1,4-benzodioxanyl)] piperazine,
- b) 1-[8-(1,3-benzodioxanyl)] piperazine,
- c) 1-[7-(benzofuranyl)] piperazine,
- d) 1-[4-(1,3-benzodioxolyl)] piperazine,
- 35 e) 1-[5-(2-methoxymethyl-1,4-benzodioxanyl)] piperazine,
- f) 1-[7-(5-fluorobenzofuranyl)] piperazine,

- g) 1-[8-(1,2,3,4-tetrahydroquinolyl)]piperazine,
h) 1-[8-(2-oxo-1-benzopyranyl)]piperazine,
i) 1-[8-(2H-1-benzopyranyl)]piperazine,
j) 1-[5-(2-methyl-1,4-benzodioxanyl)]piperazine,
5 k) 1-[7-(4-fluorobenzofuranyl)]piperazine,
l) 1-[8-(isoquinolyl)]piperazine,
m) 1-[7-(4-bromobenzofuranyl)]piperazine,
n) (+)-1-[5-(2-methoxymethyl-1,4-benzodioxanyl)]piperazine,
o) 1-[7-(4-methylbenzofuranyl)]piperazine,
10 p) 1-[7-(4-chlorobenzofuranyl)]piperazine,
q) 1-[7-(5-chlorobenzofuranyl)]piperazine.

an acid addition salt or prodrug thereof is used as the active substance.

7. A method of treating affections or diseases which are the result of disturbances in the central nervous system, characterized in that a composition as claimed in Claim 1 is administered to the patient.

8. Compounds of formula 1 of the formula sheet, in which R_1 - R_3 , A, p, n, q and m have the meanings given in Claim 1, acid addition salts, prodrugs, and enantiomers thereof, with the exception of those compounds wherein a together with the two carbon atoms of the phenyl group forms a heterocyclic group having 5 or 6 ringatoms, which as the only hetero atom contains a nitrogen atom on the meta position in relation to the piperazine group, in which $n=0$, and the group of formula 2



is a 4-(or 7-)benzimidazolyl group which may be substituted in position 2 with alkyl or phenyl, or a 7- indolyl group, or a 4-(or 7-)benzotriazolyl group, or a 5-(or 8-)carbo (or 3,4-dihydrocarbo-)styryl group, or an 8-quinoliny group.


9. Compounds

- a) 1-[5-(1,4-benzodioxanyl)] piperazine,
 b) 1-[8-(1,3-benzodioxanyl)] piperazine,
 c) 1-[7-(benzofuranyl)] piperazine,
 5 d) 1-[4-(1,3-benzodioxolyl)] piperazine,
 e) 1-[5-(2-methoxymethyl-1,4-benzodioxanyl)] piperazine,
 f) 1-[7-(5-fluorobenzofuranyl)] piperazine,
 g) 1-[8-(1,2,3,4-tetrahydroquinolyl)]piperazine,
 h) 1-[8-(2-oxo-1-benzopyranyl)]piperazine,
 10 i) 1-[8-(2H-1-benzopyranyl)]piperazine,
 j) 1-[5-(2-methyl-1,4-benzodioxanyl)]piperazine,
 k) 1-[7-(4-fluorobenzofuranyl)]piperazine,
 l) 1-[8-(isoquinolyl)]piperazine,
 m) 1-[7-(4-bromobenzofuranyl)]piperazine,
 15 n) (+)-1-[5-(2-methoxymethyl-1,4-benzodioxanyl)]piperazine,
 o) 1-[7-(4-methylbenzofuranyl)]piperazine,
 p) 1-[7-(4-chlorobenzofuranyl)]piperazine,
 q) 1-[7-(5-chlorobenzofuranyl)]piperazine.
 acid addition salts and prodrugs thereof.

20 10. A method of preparing piperazine derivatives in a manner known for the synthesis of analogous compounds, characterized in that compounds as claimed in Claim 9 are prepared by:

- a. converting a compound of formula 3


25




30

with a compound of formula 4,


35



- in which R_1-R_3 , A, p , n , q and m have the meanings given in Claim 1, and L is a leaving group; or
- b. removing from a compound of formula 1 in which the hydrogen atoms is replaced by a protective group, said protective group, for example, by means of catalytic hydrogenation or acid hydrolysis, or
- c. reducing a compound of formula 5




or formula 6,




in which R_1-R_3 , A, p , n , q and m have the meanings given in Claim 1, or


- d. converting a compound of formula 7




with a compound of formula 8,




- in which R_1 - R_3 , A , p , n , q and m have the meanings given in Claim 1, and L is a leaving group, or
- e. removing from a compound of formula 9,



- in which R_1 - R_3 , A , p , n , q and m have the meanings given in Claim 1, the amino group, or
- f. converting a compound of formula 1 into another compound of formula 1, for example, by hydrolyzing an esterified hydroxyl function, or by introducing or saturating a double bond, or
- g. converting a compound of the formula 10



- wherein A , R_1 - R_3 , m , n , p and q have the meaning given in claim 1, and R_6 is an activating group, with a compound of the formula R_2 - L , wherein R_2 has the above meaning and L is a leaving group, and removing the activating group R_6 in a way known per se, or
- h. converting a compound of formula 11,



in which Z and Z' , after cyclisation, lead to the desired group A , by means of a cyclisation reaction into a compound of formula 1, in which R_1 - R_3 , A , p , n , q and m have the meanings given in Claim 1.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT
which under Rule 45 of the European Patent Convention
shall be considered, for the purposes of subsequent
proceedings, as the European search report

0189612

Application number
EP 85 20 2085

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Y	EP- A- 0 000 121 (MERCK & CO.) * The whole document * ---	1-10	A 61 K 31/495 C 07 D 327/06 C 07 D 277/62 C 07 D 265/36 C 07 D 261/20
Y	COLLECTION OF THE CZECHOSLOV. CHEMICAL COMMUNICATIONS, vol. 40, no. 5, May 1975, pages 1612-1622, PRAGUE, CS; I. CERVENA et al.: "Naphthylpiperazines and tetralyl- piperazines: Synthesis and pharma- cological properties" * The whole article * ---	1-10	C 07 D 231/56 C 07 D 215/38 C 07 D 333/54 C 07 D 325/00 C 07 D 271/12 C 07 D 263/54 C 07 D 241/42 C 07 D 217/02 C 07 D 209/08
D, Y	GB- A- 2 086 896 (OTSUKA PHARMACEUTICALS) * The whole document * ---	1-10	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			A 61 K 31/00 C 07 D 327/00 C 07 D 277/00 C 07 D 265/00 C 07 D 261/00 C 07 D 231/00 C 07 D 215/00 C 07 D 333/00 C 07 D 325/00 C 07 D 277/00 C 07 D 263/00 C 07 D 241/00 C 07 D 217/00 C 07 D 209/00
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: 1-6, 8-10</p> <p>Claims searched incompletely: 7: Method for treatment of the human or animal body by surgery or therapy. Art. 52(4) of the European Patent Convention.</p> <p>Claims not searched: Reason for the limitation of the search:</p>			
Place of search The Hague		Date of completion of the search 24.03.1986	Examiner ALLARD
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

0189612

Application number
EP 85 20 2085

- 2 -

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,Y	GB- A- 2 097 790 (DELALANDE) * The whole document * ---	1-10	
D,Y	FR- A- 2 496 662 (OTSUKA PHARMACEUTICALS) * The whole document, particularly page 3, formula III; page 6, for- formula X; page 11, formula XXIV; page 12, formula XXVII * ---	1-10	
P,X	EP- A- 0 138 280 (DUPHAR) * The whole document * -----	1-10	TECHNICAL FIELDS SEARCHED (Int. Cl.4)